Aliskiren and blood pressure control in patients with hypertension

Comment

Donald G Vidt. Curr Hypertens Rep. 2007 Nov.

. 2007 Nov;9(5):351-2.

doi: 10.1007/s11906-007-0065-8.

No abstract available

Comment on

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Oh BH, et al. J Am Coll Cardiol. 2007 Mar 20;49(11):1157-63. doi: 10.1016/j.jacc.2006.11.032. J Am Coll Cardiol. 2007. PMID: 17367658 Clinical Trial.

Aliskiren: renin inhibitor for hypertension management.
Cheng JW. Cheng JW. Clin Ther. 2008 Jan;30(1):31-47. doi: 10.1016/j.clinthera.2008.01.011. Clin Ther. 2008. PMID: 18343241 Review.
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Andersen K, et al. J Hypertens. 2008 Mar;26(3):589-99. doi: 10.1097/HJH.0b013e3282f3ad9a. J Hypertens. 2008. PMID: 18300872 Clinical Trial.
Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.
Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Brown MJ, et al. Lancet. 2011 Jan 22;377(9762):312-20. doi: 10.1016/S0140-6736(10)62003-X. Epub 2011 Jan 12. Lancet. 2011. PMID: 21236483 Clinical Trial.
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Oh BH, et al. J Am Coll Cardiol. 2007 Mar 20;49(11):1157-63. doi: 10.1016/j.jacc.2006.11.032. J Am Coll Cardiol. 2007. PMID: 17367658 Clinical Trial.
Aliskiren: an oral renin inhibitor for the treatment of hypertension.
Lam S, Choy M. Lam S, et al. Cardiol Rev. 2007 Nov-Dec;15(6):316-23. doi: 10.1097/CRD.0b013e31814852a4. Cardiol Rev. 2007. PMID: 18090068 Review.